Athanasiou M, Blair DG, Mavrothalassitis G. ERF, an ETS-related transcriptional repressor, can induce erythroid differentiation. Anticancer Res. 2003;23:2143–53.
Peraki I, Palis J, Mavrothalassitis G. The Ets2 Repressor Factor (Erf) is required for effective primitive and definitive hematopoiesis. Mol Cell Biol. 2017;37:e00183-17.
Papadaki C, Alexiou M, Cecena G, Verykokakis M, Bilitou A, Cross JC, et al. Transcriptional repressor erf determines extraembryonic ectoderm differentiation. Mol Cell Biol. 2007;27:5201–13.
Vorgia E, Zaragkoulias A, Peraki I, Mavrothalassitis G. Suppression of Fgf2 by ETS2 repressor factor (ERF) is required for chorionic trophoblast differentiation. Mol Reprod Dev. 2017;84:286–95.
Glass GE, O’Hara J, Canham N, Cilliers D, Dunaway D, Fenwick AL, et al. ERF-related craniosynostosis: The phenotypic and developmental profile of a new craniosynostosis syndrome. Am J Med Genet A. 2019;179:615–27.
Twigg SR, Vorgia E, McGowan SJ, Peraki I, Fenwick AL, Sharma VP, et al. Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links ERK1/2 signaling to regulation of osteogenesis. Nat Genet. 2013;45:308–13.
Sgouras DN, Athanasiou MA, Beal GJ Jr, Fisher RJ, Blair DG, Mavrothalassitis GJ. ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. EMBO J. 1995;14:4781–93.
Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, et al. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature. 2017;546:671–5.
Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, et al. Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations. Cancer Discov. 2017;7:973–83.
Athanasiou M, LeGallic L, Watson DK, Blair DG, Mavrothalassitis G. Suppression of the Ewing’s sarcoma phenotype by FLI1/ERF repressor hybrids. Cancer Gene Ther. 2000;7:1188–95.
Ogura K, Elkrief A, Bowman AS, Koche RP, de Stanchina E, Benayed R, et al. Prospective clinical genomic profiling of ewing sarcoma: ERF and FGFR1 mutations as recurrent secondary alterations of potential biologic and therapeutic relevance. JCO Precis Oncol. 2022;6:e2200048.
Lackner A, Muller M, Gamperl M, Stoeva D, Langmann O, Papuchova H, et al. The Fgf/Erf/NCoR1/2 repressive axis controls trophoblast cell fate. Nat Commun. 2023;14:2559.
Vega-Sendino M, Olbrich T, Tillo D, Tran AD, Domingo CN, Franco M, et al. The ETS transcription factor ERF controls the exit from the naive pluripotent state in a MAPK-dependent manner. Sci Adv. 2021;7:eabg8306.
Polychronopoulos S, Verykokakis M, Yazicioglu MN, Sakarellos-Daitsiotis M, Cobb MH, Mavrothalassitis G. The transcriptional ETS2 repressor factor associates with active and inactive Erks through distinct FXF motifs. J Biol Chem. 2006;281:25601–11.
Chaudhry A, Sabatini P, Han L, Ray PN, Forrest C, Bowdin S. Heterozygous mutations in ERF cause syndromic craniosynostosis with multiple suture involvement. Am J Med Genet A. 2015;167A:2544–7.
Korberg I, Nowinski D, Bondeson ML, Melin M, Kolby L, Stattin EL. A progressive and complex clinical course in two family members with ERF-related craniosynostosis: a case report. BMC Med Genet. 2020;21:90.
Lee E, Le T, Zhu Y, Elakis G, Turner A, Lo W, et al. A craniosynostosis massively parallel sequencing panel study in 309 Australian and New Zealand patients: findings and recommendations. Genet Med. 2018;20:1061–8.
Moddemann MK, Kieslich M, Koenig R. Intrafamilial variability in six family members with ERF-related craniosynostosis syndrome type 4. Am J Med Genet A. 2022;188:2969–75.
Dentici ML, Niceta M, Lepri FR, Mancini C, Priolo M, Bonnard AA, et al. Loss-of-function variants in ERF are associated with a Noonan syndrome-like phenotype with or without craniosynostosis. Eur J Hum Genet. 2024;32:954–963.
Yamada M, Funato M, Kondo G, Suzuki H, Uehara T, Takenouchi T, et al. Noonan syndrome-like phenotype in a patient with heterozygous ERF truncating variant. Congenit Anom (Kyoto). 2021;61:226–30.
Calpena E, McGowan SJ, Blanco Kelly F, Boudry-Labis E, Dieux-Coeslier A, Harrison R, et al. Dissection of contiguous gene effects for deletions around ERF on chromosome 19. Hum Mutat. 2021;42:811–7.
Singh R, Cohen ASA, Poulton C, Hjortshoj TD, Akahira-Azuma M, Mendiratta G, et al. Deletion of ERF and CIC causes abnormal skull morphology and global developmental delay. Cold Spring Harb Mol Case Stud. 2021;7:a005991.
Balasubramanian M, Lord H, Levesque S, Guturu H, Thuriot F, Sillon G, et al. Chitayat syndrome: hyperphalangism, characteristic facies, hallux valgus and bronchomalacia results from a recurrent c.266A>G p.(Tyr89Cys) variant in the ERF gene. J Med Genet 2017;54:157–65.
Suter AA, Santos-Simarro F, Toerring PM, Abad Perez A, Ramos-Mejia R, Heath KE, et al. Variable pulmonary manifestations in Chitayat syndrome: Six additional affected individuals. Am J Med Genet A. 2020;182:2068–76.
Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 2010;29:2147–60.
Kaplanis J, Samocha KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature. 2020;586:757–62.
Wang T, Kim CN, Bakken TE, Gillentine MA, Henning B, Mao Y, et al. Integrated gene analyses of de novo variants from 46,612 trios with autism and developmental disorders. Proc Natl Acad Sci USA. 2022;119:e2203491119.
Alexa A, Sok P, Gross F, Albert K, Kobori E, Poti AL, et al. A non-catalytic herpesviral protein reconfigures ERK-RSK signaling by targeting kinase docking systems in the host. Nat Commun. 2022;13:472.
Ravindranath PA, Forli S, Goodsell DS, Olson AJ, Sanner MF. AutoDockFR: advances in protein-ligand docking with explicitly specified binding site flexibility. PLoS Comput Biol. 2015;11:e1004586.
Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol. 1999;292:195–202.
Zhang Y, Sanner MF. AutoDock CrankPep: combining folding and docking to predict protein-peptide complexes. Bioinformatics. 2019;35:5121–7.
Le Gallic L, Sgouras D, Beal G Jr, Mavrothalassitis G. Transcriptional repressor ERF is a Ras/mitogen-activated protein kinase target that regulates cellular proliferation. Mol Cell Biol. 1999;19:4121–33.
Le Gallic L, Virgilio L, Cohen P, Biteau B, Mavrothalassitis G. ERF nuclear shuttling, a continuous monitor of Erk activity that links it to cell cycle progression. Mol Cell Biol. 2004;24:1206–18.
Turner TN, Wilfert AB, Bakken TE, Bernier RA, Pepper MR, Zhang Z, et al. Sex-based analysis of De Novo variants in neurodevelopmental disorders. Am J Hum Genet. 2019;105:1274–85.
Treen N, Chavarria E, Weaver CJ, Brangwynne CP, Levine M. An FGF timer for zygotic genome activation. Genes Dev. 2023;37:80–5.
Vogiatzi A, Baltsavia I, Dialynas E, Theodorou V, Zhou Y, Deligianni E, et al. Erf affects commitment and differentiation of osteoprogenitor cells in cranial sutures via the retinoic acid pathway. Mol Cell Biol. 2021;41:e0014921.
Ornitz DM, Marie PJ. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev. 2015;29:1463–86.
Dash S, Trainor PA. The development, patterning and evolution of neural crest cell differentiation into cartilage and bone. Bone. 2020;137:115409.
Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5:181.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41431-024-01721-9